Showing 1,701 - 1,720 results of 15,783 for search '(( six ((nn decrease) OR (a decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 0.89s Refine Results
  1. 1701
  2. 1702

    Image_1_Astaxanthin supplementation counters exercise-induced decreases in immune-related plasma proteins.TIFF by David C. Nieman (322662)

    Published 2023
    “…Short-term astaxanthin supplementation (8 mg/day during a 4-week period) provided immune support for runners engaging in a vigorous 2.25 h running bout and uniquely countered decreases in plasma immunoglobulin levels.…”
  3. 1703
  4. 1704
  5. 1705
  6. 1706

    Decreased factor XIIIa protein levels in the tibial growth plate under PI3K inhibition. by Veronica Ulici (76661)

    Published 2010
    “…(B) Factor XIIIa protein levels were also analyzed by western blotting in both primary cell chondrocyte monolayer cultures after 24 hours and tibiae grown for six days in organ culture, showing decreased factor XIIIa protein levels under PI3K inhibition.…”
  7. 1707
  8. 1708
  9. 1709
  10. 1710
  11. 1711
  12. 1712

    Overexpression of <i>PF10_0355</i> decreases parasite susceptibility to halofantrine (HFN) and related antimalarials. by Daria Van Tyne (168938)

    Published 2011
    “…Overexpression of <i>PF10_0355</i> decreases parasite susceptibility to (A) HFN and structurally related (B) mefloquine (MFQ) and (C) lumefantrine (LUM). …”
  13. 1713
  14. 1714
  15. 1715
  16. 1716

    Western blot experiments demonstrating that TGF-β1 decreases CFTR protein abundance in HBE cells. by Steven M. Snodgrass (587391)

    Published 2013
    “…<p>(<b>A</b>) Representative experiment demonstrating that TGF-β1 decreased CFTR abundance in whole cell lysate (WCL) in a concentration-dependent manner. …”
  17. 1717
  18. 1718

    VEGFR inhibition disrupts pituitary vasculature. by Yoshito Sugita (14803627)

    Published 2023
    “…<p><b>(A-F)</b> Representative frontal sectional images of pituitaries labelled by isolectin B4 staining in control (A and D), three-day OSI-930-treated (B and E), and six-day OSI-930-treated (C and F) groups. …”
  19. 1719
  20. 1720